The genus Cannabis was first classified using the "modern" system of taxonomic nomenclature by Carl Linnaeus in 1753, who devised the system still in use for the naming of species. He considered the genus to be monotypic, having just a single species that he named Cannabis sativa L. (L. stands for Linnaeus, and indicates the authority who first named the species). Linnaeus was familiar with European hemp, which was widely cultivated at the time. In 1785, noted evolutionary biologist Jean-Baptiste de Lamarck published a description of a second species of Cannabis, which he named Cannabis indica Lam. Lamarck based his description of the newly named species on plant specimens collected in India. He described C. indica as having poorer fiber quality than C. sativa, but greater utility as an inebriant. Additional Cannabis species were proposed in the 19th century, including strains from China and Vietnam (Indo-China) assigned the names Cannabis chinensis Delile, and Cannabis gigantea Delile ex Vilmorin. However, many taxonomists found these putative species difficult to distinguish. In the early 20th century, the single-species concept was still widely accepted, except in the Soviet Union where Cannabis continued to be the subject of active taxonomic study. The name Cannabis indica was listed in various Pharmacopoeias, and was widely used to designate Cannabis suitable for the manufacture of medicinal preparations.
I just started taking CBD oil , I am on my 2nd Hip replacement surgery due to device failures looking at a 3rd surgery. Has you can imagine the pain, stress and anxiety levels are off the charts. Especially at an otherwise healthy 54 yr women. So i understand from reading posts its best to take it under the tongue. I am taking 1-2 ml a day. I can tell some difference,is your recommended dosage. I am using for pain , stress and sleep. I appreciate your feedback.
Although cannabis as a drug and industrial hemp both derive from the species Cannabis sativa and contain the psychoactive component tetrahydrocannabinol (THC), they are distinct strains with unique phytochemical compositions and uses. Hemp has lower concentrations of THC and higher concentrations of cannabidiol (CBD), which decreases or eliminates its psychoactive effects. The legality of industrial hemp varies widely between countries. Some governments regulate the concentration of THC and permit only hemp that is bred with an especially low THC content.
“Folks at the various state Departments of Agriculture are so excited to bring in hemp – excited to introduce any crop, really, and especially to reintroduce this extraordinarily versatile one,” Beckerman said. “But they’re not experts; they’re learning like anybody else. So getting in there, looking at proposed legislation and rules to make sure [proposals] actually make sense for the crop – on an agronomic level, on a regulatory level – and monitoring changes to that legislation, regulation, or industry, is common sense.” She went on,
My husband was diagnosed with ALS (amyotrophic lateral sclerosis) when he was 61 years old 4 years ago. The Rilutek (riluzole) did very little to help him. The medical team did even less. His decline was rapid and devastating. His arms weakened first, then his hands and legs. Last year, a family friend told us about Rich Herbs Foundation (RHF) and their successful ALS TREATMENT, we visited their website www. richherbsfoundation. com and ordered their ALS/MND Formula, i am happy to report the treatment effectively treated and reversed his Amyotrophic Lateral Sclerosis (ALS), most of the symptoms stopped, he is able to walk and able to ride his treadmill again, he is pretty active now.
Side effects of CBD include sleepiness, decreased appetite, diarrhea, fatigue, malaise, weakness, sleeping problems, and others. It does not have intoxicating effects like those caused by THC, and may have an opposing effect on disordered thinking and anxiety produced by THC. CBD has been found to interact with a variety of different biological targets, including cannabinoid receptors and other neurotransmitter receptors. The mechanism of action of CBD in terms of its psychoactive and therapeutic effects is not fully clear.
The use of Cannabis as a mind-altering drug has been documented by archaeological finds in prehistoric societies in Eurasia and Africa. The oldest written record of cannabis usage is the Greek historian Herodotus's reference to the central Eurasian Scythians taking cannabis steam baths. His (c. 440 BCE) Histories records, "The Scythians, as I said, take some of this hemp-seed [presumably, flowers], and, creeping under the felt coverings, throw it upon the red-hot stones; immediately it smokes, and gives out such a vapour as no Grecian vapour-bath can exceed; the Scyths, delighted, shout for joy." Classical Greeks and Romans were using cannabis, while in the Middle East, use spread throughout the Islamic empire to North Africa. In 1545, cannabis spread to the western hemisphere where Spaniards imported it to Chile for its use as fiber. In North America, cannabis, in the form of hemp, was grown for use in rope, clothing and paper.
More recently, Sakamoto and various co-authors have used RAPD to isolate several genetic marker sequences that they name Male-Associated DNA in Cannabis (MADC), and which they interpret as indirect evidence of a male chromosome. Several other research groups have reported identification of male-associated markers using RAPD and AFLP. Ainsworth commented on these findings, stating,
Fiberboard. In North America the use of nonwood fibers in sheet fiberboard (“pressboard” or “composite board”) products is relatively undeveloped. Flax, jute, kenaf, hemp, and wheat straw can be used to make composite board. Wheat straw is the dominant nonwood fiber in such applications. Although it might seem that hemp bast fibers are desirable in composite wood products because of their length and strength, in fact the short fibers of the hurds have been found to produce a superior product (K. Domier, pers. commun.). Experimental production of hemp fiberboard has produced extremely strong material (Fig. 22). The economic viability of such remains to be tested. Molded fiberboard products are commercially viable in Europe (Fig. 23), but their potential in North America remains to be determined.
Karl W. Hillig, a graduate student in the laboratory of long-time Cannabis researcher Paul G. Mahlberg at Indiana University, conducted a systematic investigation of genetic, morphological, and chemotaxonomic variation among 157 Cannabis accessions of known geographic origin, including fiber, drug, and feral populations. In 2004, Hillig and Mahlberg published a chemotaxonomic analysis of cannabinoid variation in their Cannabis germplasm collection. They used gas chromatography to determine cannabinoid content and to infer allele frequencies of the gene that controls CBD and THC production within the studied populations, and concluded that the patterns of cannabinoid variation support recognition of C. sativa and C. indica as separate species, but not C. ruderalis. The authors assigned fiber/seed landraces and feral populations from Europe, Central Asia, and Turkey to C. sativa. Narrow-leaflet and wide-leaflet drug accessions, southern and eastern Asian hemp accessions, and feral Himalayan populations were assigned to C. indica. In 2005, Hillig published a genetic analysis of the same set of accessions (this paper was the first in the series, but was delayed in publication), and proposed a three-species classification, recognizing C. sativa, C. indica, and (tentatively) C. ruderalis. In his doctoral dissertation published the same year, Hillig stated that principal components analysis of phenotypic (morphological) traits failed to differentiate the putative species, but that canonical variates analysis resulted in a high degree of discrimination of the putative species and infraspecific taxa. Another paper in the series on chemotaxonomic variation in the terpenoid content of the essential oil of Cannabis revealed that several wide-leaflet drug strains in the collection had relatively high levels of certain sesquiterpene alcohols, including guaiol and isomers of eudesmol, that set them apart from the other putative taxa. Hillig concluded that the patterns of genetic, morphological, and chemotaxonomic variation support recognition of C. sativa and C. indica as separate species. He also concluded there is little support to treat C. ruderalis as a separate species from C. sativa at this time, but more research on wild and weedy populations is needed because they were underrepresented in their collection.
Yet when one looks at the industry more broadly, there is cause for concern. In February, as part of an investigation into the marketing claims of six hemp oil companies, the FDA analyzed 18 CBD products. What it found was disturbing: Many of these supposed CBD products were entirely lacking in CBD. Of the products tested, six contained no cannabinoids whatsoever. Another 11 contained less than 1 percent CBD. The product that tested highest in CBD, at 2.6 percent, was a capsule for dogs. In states that have legalized CBD, regulations can require CBD products to contain at least 5 percent CBD, more often 10 or 15 percent.
Categories: English terms borrowed from LatinEnglish terms derived from LatinEnglish terms derived from Ancient GreekEnglish doubletsEnglish 3-syllable wordsEnglish terms with IPA pronunciationEnglish terms with audio linksEnglish lemmasEnglish nounsEnglish uncountable nounsEnglish countable nounsen:Marijuanaen:Rosales order plantsFrench terms borrowed from LatinFrench terms derived from LatinFrench terms derived from Ancient GreekFrench doubletsFrench 3-syllable wordsFrench terms with IPA pronunciationFrench lemmasFrench nounsFrench masculine nounsFrench uncountable nounsfr:Recreational drugsLatin terms derived from Ancient GreekLatin 3-syllable wordsLatin terms with IPA pronunciationLatin lemmasLatin nounsLatin feminine nounsLatin third declension nounsLatin feminine nouns in the third declensionLatin non-lemma formsLatin noun formsla:PlantsNorman terms borrowed from LatinNorman terms derived from LatinNorman terms derived from Ancient GreekNorman lemmasNorman nounsnrf:Plantsnrf:Recreational drugsSpanish terms borrowed from LatinSpanish terms derived from LatinSpanish terms derived from Ancient GreekSpanish doubletsSpanish lemmasSpanish nounsSpanish uncountable nounses:Recreational drugsSwedish terms borrowed from LatinSwedish terms derived from LatinSwedish lemmasSwedish nounssv:Plantssv:Recreational drugs
^ Jump up to: a b Schreiner AM, Dunn ME (October 2012). "Residual effects of cannabis use on neurocognitive performance after prolonged abstinence: a meta-analysis". Experimental and Clinical Psychopharmacology. 20 (5): 420–429. doi:10.1037/a0029117. PMID 22731735. Therefore, results indicate evidence for small neurocognitive effects that persist after the period of acute intoxication...As hypothesized, the meta-analysis conducted on studies eval- uating users after at least 25 days of abstention found no residual effects on cognitive performance...These results fail to support the idea that heavy cannabis use may result in long-term, persistent effects on neuropsychological functioning.
The objectivity of scientific evaluation of the medicinal value of marijuana to date has been questioned. In the words of Hirst et al. (1998): “The ...status of cannabis has made modern clinical research almost impossible. This is primarily because of the legal, ethical and bureaucratic difficulties in conducting trials with patients. Additionally, the general attitude towards cannabis, in which it is seen only as a drug of abuse and addiction, has not helped.” In a recent editorial, the respected journal Nature (2001) stated: “Governments, including the US federal government, have until recently refused to sanction the medical use of marijuana, and have also done what they can to prevent its clinical testing. They have defended their inaction by claiming that either step would signal to the public a softening of the so-called ‘war on drugs.’... The pharmacology of cannabinoids is a valid field of scientific investigation. Pharmacologists have the tools and the methodologies to realize its considerable potential, provided the political climate permits them to do so.” Given these current demands for research on medicinal marijuana, it will be necessary to produce crops of drug types of C. sativa.